Are Regulations Safe? Reflections From Developing a Digital Cancer Decision-Support Tool

Ciarán D. McInerney, PhD; Beverly C. Scott, MSc; and Owen A. Johnson, MSc

abstract

PURPOSE Informatics solutions to early diagnosis of cancer in primary care are increasingly prevalent, but it is not clear whether existing and planned standards and regulations sufficiently address patients’ safety nor whether these standards are fit for purpose. We use a patient safety perspective to reflect on the development of a computerized cancer risk assessment tool embedded within a UK primary care electronic health record system.

METHODS We developed a computerized version of the CAncer Prevention in ExeterER studies risk assessment tool, in compliance with the European Union’s Medical Device Regulations. The process of building this tool afforded an opportunity to reflect on clinical concerns and whether current regulations for medical devices are fit for purpose. We identified concerns for patient safety and developed nine practical recommendations to mitigate these concerns.

RESULTS We noted that medical device regulations (1) were initially created for hardware devices rather than software, (2) offer one-shot approval rather than supporting iterative innovation and learning, (3) are biased toward loss-transfer approaches that attempt to manage the fallout of harm instead of mitigating hazards becoming harmful, and (4) are biased toward known hazards, despite unknown hazards being an expected consequence of healthcare as a complex adaptive system. Our nine recommendations focus on embedding less-reductionist and stronger system perspectives into regulations and standards.

CONCLUSION Our intention is to share our experience to support research-led collaborative development of health informatics solutions in cancer. We argue that regulations in the European Union do not sufficiently address the complexity of healthcare information systems with consequences for patient safety. Future standards and regulations should continue to follow a system-based approach to risk, safety, and accident avoidance.

JCO Clin Cancer Inform 5:353-363. © 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION

Clinical decision-support tools in primary care can help clinicians make an early diagnosis of cancer, leading to better outcomes for the patient and a more effective use of limited healthcare resources. Informatics solutions are increasingly being adopted, but it is not clear whether existing and planned standards and regulations sufficiently address patient safety nor whether these standards are fit for purpose when embedded within complex and evolving health information systems. The patient safety consequences of rapid development and implementation of such computerized tools are not yet known. Regulatory standards have been developed for clinical decision-support tools in the United States and Europe, but it is not clear whether these sufficiently address patient safety. This paper presents a case study in clinical cancer informatics to reflect on whether current standards are fit for purpose.

Survival rates are better for early-stage diagnoses across many cancers, and early diagnosis is recognized as a key determinant of improved outcomes. Early diagnosis in primary care can be challenging where multiple vague symptoms might be reported. In the United Kingdom, primary care General Practitioners (GPs) sometimes delay referral for cancer investigation and some GPs require high levels of suspicion before referring. In an effort to minimize delay, clinical decision-support tools and systems can assist GPs to expedite referrals and contribute to earlier diagnosis by recommending an appropriate diagnostic pathway.

There are many kinds of decision support with mixed evidence of effectiveness. Symptom checker applications can be used to prompt patients who might otherwise delay a referral because they have trivialized symptoms. Symptoms lacking objective measurement—such as coughing and fatigue—are
not always considered with due weight because they are often common and nonspecific, despite being strongly indicative for some conditions. Examples in the UK National Health Service (NHS) include QRisk3, QCancer, and Cancer risk assessment tools (RATs), for which there is evidence of acceptability and positive effect on referral rates.

Computerized decision support offers benefits over paper-based alternatives through automation, consideration of all data in the patient’s electronic record, computing suggestions faster than by hand, and providing the potential for prompts at optimal points in the clinical pathway. Computerized decision support is often compared against paper-based counterparts on the assumption that the paper versions are a suitable gold standard. On the contrary, a meta-regression analysis of the effect of clinical decision support on clinical performances of interest suggested that computerized decision support was associated with greater improvements compared with their non-digital counterparts. As the COVID-19 pandemic accelerates the drive to digital healthcare systems, the persistence of paper-based methods as the primary modality (as opposed to contingency) makes integration difficult and compromises health system performance and thus the safety of patients.

Regardless of its advantages, clinical decision-support software is recognized as safety critical, which means that errors in use can cause significant harm. However, as noted in Miller’s 2009 historical review, the history of computer-aided, diagnostic, decision support makes little to no mention of a safety perspective. Decision-support software can be inappropriately ad hoc in its development, which has prompted regulation and accreditation in different parts of the world including Europe, with, for example, the Medical Device Directive, Conformité Européenne (CE) marking, and the Medical Device Regulation (MDR). An introductory guide can be found in Medicines and Healthcare products Regulatory Agency: An Introductory Guide to the Medical Device Regulation (MDR) and the In Vitro Diagnostic Medical Device Regulation (IVDR). Although progress has been made in the creation of methods for software development, like Discipline Agile Delivery, the focus has been on the technical performance given initial requirement specifications that do not always include safety. This is despite calls from as far back in the 1980s for an acceptable safety level to be designed into software systems before actual production or operation.

Standards and Regulations for Clinical Decision-Support Systems

Reviews and summaries of some regulations have been conducted, but the safety implications of clinical decision tools like symptom checkers are still underappreciated. In the European Union, the Medical Device Directive specifies classifications for different levels of regulation, essential requirements for each level, and conformity routes for medical devices. It was due for a replacement with the MDR in 2020, but this deadline was extended to 2021 because of the COVID-19 pandemic. The intended improvements of the MDR included postmarket surveillance, registration databases of devices and independent accreditors, unique device identification, novel device classifications (notably for software), and additional evidence requirements. Notably, the MDR regulates medical devices but does not specify standards.

No single standard sufficiently covers the scope of clinical decision-support systems. Helpfully, Chadwick et al summarize the relevant standards in their review and introduction to IEC 61508. The IEC 61508 is a standard suggested by the International Electrotechnical Commission (IEC) that describes methods for designing, deploying, and maintaining automatic protection systems. Chadwick et al argue that IEC 61508 is the most appropriate standard to reference when considering any medical device software because of its safety and systems perspective.
In the United Kingdom, where this research was conducted, specific standards include DCB012938 for health system suppliers and DCB016039 for health service organizations, both developed for the UK NHS by the NHS Digital Clinical Safety Group. Other relevant standards are the International Organization for Standardization (ISO) 14971:2012, which details the internationally harmonized medical device risk management standard that covers general medical device development, but not software; the IEC Technical Report (IEC/TR) 80002-1:2009, which provides guidance on the application of ISO 14971 to medical device software; and IEC 62304:2006, which outlines the principles of software safety classification and software lifecycle for medical devices.

Although these standards are available, they are not compulsory. In the European Union’s MDR, CE marking is the requirement for devices that go into service, whether or not they go to market (Sec. 2 Art.52(2)27). CE marking is a declaration by a manufacturer, indicating that they take responsibility for the conformity of the product with the essential requirements of the relevant European health, safety, and environmental protection legislation.26 As noted by Altenstetter,35 it “serves as a kind of market authorization but should not be confused with premarket approval of individual products, or with the strict product testing regime operative in the pharmaceutical sector.” Shortcomings of CE marking have been explained elsewhere noting, for example, that the product can be tested for safety without being tested for effectiveness.40 The following safety-specific criticisms of CE marking are worth noting (for more details, see refs. 35,41):

- Manufacturers do not need to provide instructions for safe use if they believe that the device can be used safely without instructions (Annex I Chapter III § 23.1.d27). This places the responsibility of safety assessment, risk assessment, and risk control in the hands of the manufacturer who might not have sufficient knowledge or capacity to do so and who has competing financial incentives;42
- The classification rules should be based on the intended use of the device (Annex VIII Chapter II ¶ 3.127), which does not acknowledge harm that might arise from misuse—one of the three suggested domains of health information-technology safety;43
- The classification rules should be applied separately to devices that are intended to be used in combination (Annex VIII Chapter II ¶ 3.227), which does not consider the unknown behaviors that can emerge when healthcare information technologies combine to form health information systems.44,45

The greatest concern is that these safety insufficiencies relate to all classifications, including class I, which has the least oversight and requirements (Annex VIII Chapter II27). Manufacturers can accredit their own devices as class I, needing only to make available for possible inspection a technical file detailing a self-determined assessment of conformity to standards. There is a danger that manufacturers of class I devices do not consider the more-advanced standards discussed previously and put products to market that are not sufficiently safe for patients, albeit they conform to regulations. Any self-certification or other less-stringent route to approval runs the risk of misuse or abuse at the cost of patient safety. For example, the review by Zuckerman et al46 on device recalls in the United States showed 71% of recalls were for devices approved via the route that did not require clinical trials or manufacturer inspections of safety or efficacy (see ref. 47 for discussion of differences between European Union and US systems, at the time).

A further complication is when software is developed for exclusive use within particular health service organizations, which is associated with its own lesser regulation in the United Kingdom.48 Finally, decision-support software can sit within or on top of an electronic healthcare record with the best intentions of integration in mind. In such cases, the boundaries of legal responsibility and of what constitutes new or existing software are unclear. Examples of software include STarT BACK, a back pain RAT integrated into an electronic health record system,49 and BMJ Informatica’s implementation of Hamilton’s19 Cancer RAT, which interfaces with the electronic health record system.13

In a previous paper in this journal, we described the development of a clinical decision-support tool with a focus on usability and clinical utility.30 In this paper, we take a patient safety perspective to describe a case study of the development of a computerized, clinical decision-support system for cancer risk assessment embedded within an electronic health record system. As a class I medical device, the tool requires minimal consideration for patient safety despite influencing clinical decisions that, while not therapeutic nor diagnostic, nevertheless affect patient care and their journey through the health system. We argue that current European regulations are insufficient for facilitating safe development of healthcare information technology. Our intention is to share our experience to support research-led collaborative development of health information technology.

**CASE STUDY**

**Description**

The risk assessment system we implemented was a computerization of Hamilton’s cancer RATs from the Cancer Prevention in Exeter (CAPE) studies (Fig 1A). There is strong case for computerization of Hamilton’s cancer RATs because these studies identified features associated with subsequent cancer diagnosis that was clinically coded within patients’ electronic health records.19 The computerization also facilitates distribution of the tool through the UK primary care software systems, which can normalize and automate symptom detection.
The English NHS has approved four electronic health record systems for use in primary care, and these have 100% adoption with the three dominant systems being The Phoenix Partnership (TPP) SystmOne, EMIS, and Vision. CAPER RATs have been computerized by Macmillan Cancer Support into Vision and EMIS Health systems50; Our case study reports on development within SystmOne.51 The Macmillan Cancer Support implementations covered lung cancer and colorectal cancer, whereas our work included bladder,52 colorectal,53 kidney,54]lung,55 esophagogastric,56 and ovarian cancers.57 We did not implement the audit-
table function available in the Macmillan Cancer Support implementations but did implement in-consultation prompts and an interactive symptom checker. The in-consultation prompt is an automated function that computed and presented a patient’s CAPER RAT score for each cancer when the patient’s record was retrieved at the start of the consultation. The symptom checker was a clinician-selected form that structures a patient discussion on other potentially relevant symptoms to compute a CAPER RAT score. We began by assessing the feasibility of creating the electronic-RAT within TPP SystmOne Demo version.

**FIG 1.** (A) Adaptation of the paper-based CAPER colorectal risk assessment tool (approved by original authors). (B) Screenshot of the eRAT prompt that is automatically generated when a consultation has begun or generated on demand by the user. CAPER, Cancer Prevention in Exeter; eRAT, electronic-RAT.

| Constipation | Diarrhoea | Rectal bleeding | Loss of weight | Abdominal pain | Abdominal tenderness | Abdominal rectal exam | Haemoglobin 10–13 g/dl | Haemoglobin <10 g/dl | PPV as a single symptom |
|--------------|-----------|-----------------|----------------|---------------|---------------------|----------------------|----------------------|-------------------------|------------------------|
| 0.40         | 0.94      | 2.40            | 1.20           | 1.10          | 1.10                | 1.50                 | 0.97                 | 2.30                    | Constipation            |
| 0.81         | 1.10      | 2.40            | 3.00           | 1.50          | 1.70                | 2.60                 | 1.20                 | 2.60                    | Diarrhoea              |
| 1.50         | 3.40      | 3.10            | 1.90           | 2.40          | 11.0                | 2.20                 | 2.90                 | Rectal bleeding         |
| 6.80         | 4.70      | 3.10            | 4.50           | 8.50          | 3.60                | 3.20                 |                      |                         |
| 1.40         | 3.40      | 6.40            | 7.40           | 1.30          | 4.70                |                      |                      |                         |
| 3.00         | 1.40      | 3.30            | 2.20           | 6.90          |                     |                      |                      |                         |
| 1.70         | 5.80      | 2.70            | >10            |              |                     |                      |                      |                         |

The tool suggests the following “risk” scores:

| Cancer     | Score |
|------------|-------|
| Colorectal | 5.25  |
| Lung       | 2.3   |
| Ovarian    | 5     |

Any scores > 5% = High Risk (suggest a referral)
Any scores > 2% = Moderate Risk (suggest a referral of review of symptoms)

Would you like to make a Referral or use the Symptom Checker tool to gather more information?
TABLE 1. Requirements for Class 1 Medical Devices Stipulated by the Medical Device Regulations

| Annex 2                  | 1. Device description and specification. |
|--------------------------|----------------------------------------|
| Technical documentation  | 2. Information to be supplied by the manufacturer. |
|                          | 3. Design and manufacturing information. |
|                          | 4. General safety and performance requirements. |
|                          | 5. Benefit-risk analysis and risk management plan. |
|                          | 6. Documentation in support of all verifications and validations that demonstrate conformity. |
| Annex 3                  | 1. Postmarket surveillance plan. |
| Technical documentation on postmarket surveillance | 2. Postmarket surveillance report. |
| Annex 4                  | 1. European Union declaration of conformity |

SystmOne offers functionality to users for triggering automated protocols, developing e-forms to collect data, and defining bespoke clinical reports. It proved to be feasible to develop a prototype system using automated protocols to calculate an RAT score by processing bespoke clinical reports that queried a patient’s records for symptoms (Fig 1B). It was also feasible to build a Symptom Checker e-form for focusing consultations.

Such a system would be considered a class 1 medical device as per the MDR because it is a noninvasive device (Annex VIII Chapter III ¶ 4.1 Rule 1) that, although an active device (Art. 2[4]), is not intended to take decisions with diagnosis or therapeutic purposes (Annex VIII Chapter III ¶ 6.3 Rule 11). The requirements for a class 1 device are shown in Table 1.27

In the interests of maintaining a patient safety perspective, we will focus discussions on the General Safety and Performance Requirements and Benefit-Risk Analysis and Risk Management as described in Annex 1 and 2 of the MDR. Much of the requirements can be summarized within our software development lifecycle (Fig 2). We iterated the first three stages of the software development lifecycle to incorporate insight gained from attempted builds and ongoing communication with TPP and a consultant in MDR (author B.S.). For risk management, we integrated elements of ISO 14971:2012, IEC/TR 80002-1:2009, and IEC 62304:2006, as described in the introduction. We deemed our risk management planning to be compliant with ISO 13485:2016, ISO 14971:2012, IEC/TR 80002-1:2009, DCB0129:2018, IEC 62304:2006 Amd 1:2015, and BS EN 62366-1:2015.

Reflections

One-shot deal versus gradual reciprocity. Our iterative development approach prompted reflection on the safety standards and regulations. We noted that current regulations offer a one-shot deal wherein manufacturers are judged on a finished product produced by following self-determined standards. If the device fails review, the manufacturer must restart product development. This is costly for manufacturers, which likely both discourages innovation and hinders learning. Gradual and reciprocal development and safety review might be preferable to encourage manufacturer engagement and integration of safety into device development.

Hazard of assuming benignity. Manufacturers’ self-classification of devices’ safety class is fundamental to the MDR. The safety classification rules in the MDR diligently classify devices that are expected to be potentially harmful and classify other devices with lesser concern. The implicit bias toward known hazards over unknown ones falls prey to the potential for emergent harm that, by definition, cannot be predicted (or are at least difficult to predict precisely). As a complex system, healthcare provision and regulation operate with a prediction horizon.58 Far from ignoring or downplaying the events beyond this horizon, regulators should endeavor to prepare for such events as best as they can, similar to how they currently request manufacturers to foresee and prepare for consequences of a device’s use. The extreme alternative to Rule 13 (ie, all other active devices are classified as class I) is to say that all devices that are not classified with previous rules must be subject to review by the Notified Body. From the latter perspective, the unknown is approached with caution rather than assumed benignity.

Bias toward loss transfer. We also note that the regulations and standards have an unbalanced approach to loss assessment, loss control, and loss transfer. As noted by Chadwick et al, standards like IEC 80001 are welcomed for their systemic consideration of information technology networks rather than isolated medical devices. However, IEC 80001 suggests that hospitals are solely responsible for the shared system configurations that they use, regardless of what options are available. This framework invites the well-known safety science criticisms of responsibility structures, wherein those downstream in the resource-to-delivery pipeline are responsible for harms that might have their origin as upstream hazards.59,60 Such responsibility structures lend themselves to focusing safety efforts at the
sharp end of systems rather than further back in the causal chain.

For example, CE marking does not evidence the safety of a device so much as it evidences that a legal entity (the manufacturer) takes responsibility for adherence to safety regulations. Although the intention might be to encourage the legal entity to minimize the risk of harm potentially caused by the product, a simpler solution to adherence can be reached with an insurance model for handling risk, which is part of a loss-transfer approach. Such an approach attempts to manage the fallout of harm instead of upstream mitigation of hazards becoming harm.

To illustrate the incoherence between safety and loss-transfer approaches, consider insurance premiums for drivers. Premiums are an attempt to cover the costs of road traffic accidents but do not attempt to influence the risk of accidents, which is the product of likelihood and the magnitude of harm. On the other hand, speed limits attempt to decrease the likelihood of accidents occurring and have been shown to influence the risk of road traffic accidents. Thus, speed limits facilitate safety by addressing the harm-generating process further back in the causal chain, which is the intention behind the risk management planning requirements of CE marking.

The loss-transfer approach might be used when the likelihood of harm is low, but the magnitude is high, and when the use of resources is valued using short- and medium-term perspectives. This tactic is likely due to a misunderstanding of probability that interprets a low-probability event as the one that will not happen until the distant future, as opposed to the one that can happen at any time. When combined with humans’ tendency for temporal discounting, the choice is made to endure the harm of low likelihood-high magnitude events in the future rather than mitigating them at present. Commercial entities with sufficient collateral can absorb the consequences of safety risks by playing the odds while a product earns in the market. On the contrary, it is more difficult to get products to market with patient safety insights from patient caregivers and safety researchers because existing regulations are not primarily designed for clinical and academic institutions to lead on development. The presence of a commercial bias was evidenced by a 2020 study showing that the public discourse around a regulatory framework for software as a medical device proposed by US Food and Drug Administration lacked scientific support and commonly involved undisclosed financial ties with industry.

Despite these criticisms, loss-transfer approaches are rational choices when it is more difficult to predict the behavior of a complex system than it is to manage its...
undesirable consequences. A dynamic approach to risk
management that acknowledges a prediction horizon,
multiple levels, dependencies, and adaptations is thus
needed. The loss-transfer approach has been useful for
handling harm but ultimately should only be considered a
stopgap while we improve our understanding of harm-
generating processes in the healthcare systems.

**PATIENT SAFETY RECOMMENDATIONS**

Our experience of developing a computerized clinical
decision-support system provided insight into the potential
treatments to patient safety inherent in the regulation of
medical devices. Table 2 presents nine recommendations
to address our identified concerns and the expected
improvements for patient safety.

Beginning with perhaps the most practicable suggestion,
we recommend an explicit rather than implicit definition of
class 1 devices, which could be managed by notified
bodies [recommendation 1]. As noted in earlier reflections,
classification of class 1 devices is implied when not covered
by predetermined hazards. An alternative is for unclassified
devices to be subject to review by the Notified Body.

A second practicable suggestion is for explicit harmonized
regulation of devices developed in-house [recommendation
2]. There is intentional lack of regulatory requirements for
medical devices developed in-house that assumes regulations
should not apply to devices “used only within health
institutions...that support the healthcare system and/or
address patient needs...since the aims of this Regulation
would still be met in a proportionate manner.” 27(p)

Although we do not doubt healthcare institution’s commit-
mant to patient safety, there is concern about competing
incentives, less-stringent national regulations, and lack of
knowledge and experience evaluating safety of medical
devices.

It is already accepted by the clinical academic community
that the regulation of medical devices is unfit to protect
patients against harm, with thwarted calls for medical
devices to be regulated like pharmaceuticals. At first
anxiety, it might seem to be preferable to adopt the more
stringent regulatory frameworks used by the European
Medicines Agency. These frameworks take a strong
Safety-1 approach, which is more concerned with mini-
Sizing false negatives than it is about promoting true
positives, in other words, stopping unsafe and ineffectice
devices getting to market even at the expense of hindering
access to safe and effective devices. But the rapid in-
novation of medical devices does not lend itself well to
such prolonged evaluations. The Safety-2 paradigm of
Hollnagel et al, however, focuses on promoting

---

**TABLE 2. Summary of Recommendations to Address the Safety Concerns Raised. Expected Improvements to Patient Safety Are Also Provided**

| No. | Recommendation | General Concern Being Addressed | Patient Safety Improvement |
|-----|----------------|---------------------------------|---------------------------|
| 1   | Involve notified body in regulation of Class 1 devices | Classification of Class 1 devices is implicit if not covered by predetermined hazards and is not checked by notified bodies, so they might be inappropriately less scrutinised. | Greater opportunity for appropriate classification of risk. |
| 2   | Explicit harmonized regulation of devices developed in-house | Insufficient expertise and guidance. | Holistic and integrated approach to device development. |
| 3   | Safety-2 perspective of risk | Over focus on stopping things going wrong at the risk of hindering innovation | Patients awal of manageable risky innovations. |
| 4   | Gradual approval of medical devices (eg, IDEAL framework) | Current regulation cannot handle incremental rollout and development, which are cornerstones of software and needed for cautious evaluation of emergent behavior. | Manageably increased sensitivity to safety concerns during evaluation. |
| 5   | Risk-sharing approach | Responsibility for risk mitigation is solely on the manufacturer despite the fact that the safe development and use of devices involve multiple stakeholders. Also, loss-transfer approaches like insurance inevitably discourage innovators with less financial collateral. | Broad and less-biased concept of risk. |
| 6   | Realign standards and regulations | Current regulations are decoupled from standards, which permits gaming to expedite product to market. | Constraints on perverse actions. |
| 7   | Systems approach to conceptualizing risk | Current regulation is biased toward handling known harms despite the complex nature of healthcare, meaning that some harms are emergent. Also, risk classification is separate for components intended to be used together, which ignores the potential for emergent harms from interactions. | Increased sensitivity to emergent threats to patient safety. |
| 8   | Systems approach to patient safety | Current regulation does not conceptualize health care as a complex system so the underlying conception of patient safety is inaccurate. | Better understanding of what the structure of patient safety might be. |
| 9   | Systems model of accidents | Current regulation does not conceptualize health care as a complex system so the underlying conception of causation is inaccurate. | Better understanding of what the mechanism of harm generation might be. |

Abbreviation: IDEAL, Idea-Development-Exploration-Assessment-Long.
processes that lead to safe performance despite the presence of hazard, by dynamically reflecting and adjusting performance. Future regulations could benefit from adopting a Safety-2 approach to their design [recommendation 3].

Computerized decision-support systems are complex interventions and should be evaluated as such. Nieuwenhuijsen et al. suggest a regulatory approach reminiscent of Safety-2 by requiring controlled and evidence-based introductions of device innovations to safely handle upgrades, in their case, to orthopedic medical implants. This is one approach to regulate incremental innovation in medical devices, of which the development of software-within-software could be considered an example. On a similar vein, the Idea-Development-Exploration-Assessment-Long-term framework champions gradual approval of medical devices rather than the one-shot approval of CE marking, which would allow graded, responsible, but earlier patient access. In the United States, the Software Pre-Cert Pilot Program focuses on the digital health technology developer rather than the product to support streamlined premarket review and learning from use in the market. Such frameworks address the concern that the increased administrative burden of more stringent regulations might delay products that are imperfect but practically useful [recommendation 4].

With respect to standards, we encourage risk sharing approaches, as promoted by ISO 31000 [recommendation 5]. Such approaches distribute loss assessment, loss control, and loss transfer over all stakeholders at the cost of more complicated relationships between producers, providers, and users. This increased complicatedness of relationships will require resources, but such expense should be seen as an investment in improved system performance, rather than an inconvenience.

If not risk sharing, at least an alternative to predominantly loss-transfer approaches would be an increase in the focus of loss-control approaches like risk mitigation. These approaches are the second of three elements of a thorough risk management strategy for patient safety. Although design control and risk management are explicitly mentioned in standards like ISO 13485, risk control is not explicitly mandated. Realignment of law and technical standards in the European Union might be required to facilitate this [recommendation 6].

Of course, loss-control approaches are insufficient on their own. Health care is inherently risky and must approach safety by concurrently avoiding, managing, and embracing risk, depending on which of its range of services it is providing. Although regulation contributes to the avoidance and management of risk, it is not well-placed to help with embracing risk, which requires adaptive processes within the healthcare systems. The proposed solution is for actors in such an environment or system to rely on personal (rather than system) judgment, adaptability, and resilience.

On the theme of complex systems, ISO 14971 recommends proactive identification and mitigation of hazards, which assumes at least an approximately deterministic system in which hazards and harms can be foreseen. Health care, however, is a complex adaptive system whose behavior can be emergent, nonlinear, and intractable to predict at arbitrary horizons. An alternative system–based approach to conceptualizing risk is required to appropriately reflect the systems being regulated [recommendation 7], which should be complemented by system-based approaches to patient safety [recommendation 8] and models of accidents, eg, Levenson’s System-Theoretic model [recommendation 9].

Criticisms of the European Union’s MDD have partly been addressed in the impending MDR. It has become increasingly apparent, however, that existing regulation of medical devices is insufficient for the digital age and there are difficulties inherent in reaching global coherence. In this article, we argue that regulations in the European Union do not sufficiently address the complexity of healthcare information systems with consequences for patients’ safety. Advocates for digital health care tout its speed, coverage, and capacity but perhaps without considering its own suite of challenges. Future development of regulations should make it easier for clinical and academic institutions to produce healthcare information technology so that they contribute their patient care and safety science insights. Finally, future development of standards should continue to follow a system-based view to risk of healthcare information technology.

AFFILIATIONS
1School of Computing, University of Leeds, Leeds, United Kingdom
2BCS Clinical Consulting, Chesterfield, United Kingdom

CORRESPONDING AUTHOR
Ciarán D. McInerney, PhD, University of Leeds, E.C. Stoner Building, Leeds, LS1 9JT, United Kingdom; e-mail: c.mcinerney@leeds.ac.uk.

DISCLAIMER
The views expressed in this article/presentation are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health and Social Care.

SUPPORT
Supported by the National Institute for Health Research (NIHR) Yorkshire and Humber Patient Safety Translational Research Center (NIHR Yorkshire and Humber PSTRC).

AUTHOR CONTRIBUTIONS
Conception and design: Ciarán D. McInerney, Owen A. Johnson
Financial support: Owen A. Johnson
Administrative support: Beverly C. Scott
REFERENCES

1. Emery JD, Shaw K, Williams B, et al: The role of primary care in early detection and follow-up of cancer. Nat Publ Gr 11:38-48, 2014
2. US Food and Drug Administration: Software as a Medical Device (SAMD): Clinical Evaluation Guidance for Industry and Food and Drug Administration Staff. FDA Guideline, 2017, pp 1-32. https://www.fda.gov/media/100714/download
3. The European Parliament and The Council of the European Union: Council Directive 93/68/EEC of 22 July 1993. Off J Eur Union 68, 1993
4. Steele CB, Li J, Huang B, et al: Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer 123:5160-5177, 2017
5. Alawadhi E, Al-Awadi A, Eibasmi A, et al: Cancer survival by stage at diagnosis in Kuwait: A population-based study. J Oncol 2019:8463195, 2019
6. Matz M, Coleman MP, Carreira H, et al: Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol 164:396-404, 2017
7. Siegel RL, Miller KD, Jemal A: Cancer statistics. CA Cancer J Clin 67:7-30, 2018
8. Hamilton WT, Walter FM, Rubin GP, et al: Improving early diagnosis of symptomatic cancer. Nat Rev Clin Oncol 13:740-749, 2016
9. Rubin GP, Saunders CL, Abel GA, et al: Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: Analysis of national primary care audit data. Br J Cancer 112:676-687, 2015
10. Wagland R, Brindle L, James E, et al: Facilitating early diagnosis of lung cancer amongst primary care patients: The views of GPs. Eur J Cancer Care (Engl) 26:1-8, 2017
11. Walter FM, Webster A, Scott S, et al: The Andersen model of total patient delay: A systematic review of its application in cancer diagnosis. J Health Serv Res Policy 17:110-118, 2012
12. Usher-Smith JA, Silarova B, Sharp SJ, et al: Effect of interventions incorporating personalised cancer risk information on intentions and behaviour: A systematic review and meta-analysis of randomised controlled trials. BMJ Open 8:1-13, 2018
13. Usher-Smith JA, Emery JD, Hamilton WT, et al: Risk prediction tools for cancer in primary care. Br J Cancer 113:1645-1650, 2015
14. Stacey D, Légaré F, Lewis K, et al: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 4:CD001431, 2017
15. Kuziemsky CE, Eynakchi R, Jibb L, et al: Digital process innovation for patient centred cancer symptom management. Stud Health Technol Inform 257:250-255, 2019
16. Olsen CM, Crossen J, Green AC, et al: Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol 28:376-380, 2007
17. Hipsipio-Coax J, Coupland C, Brindle P: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ 357:1-21, 2017
18. Hipsipio-Coax J, Coupland C: Identifying patients with suspected lung cancer in primary care: Derivation and validation of an algorithm. Br J Gen Pract 61:e715, 2011
19. Hamilton WT: The CAPER studies: Five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. Br J Cancer 101:580-586, 2009
20. Hamilton WT, Green T, Martins T, et al: Evaluation of risk assessment tools for suspected cancer in general practice: A cohort study. Br J Gen Pract 63:30-36, 2013
21. Bobb AM, Payne TH, Gross PA: Viewpoint: Controversies surrounding use of order sets for clinical decision support in computerized provider order entry. J Am Med Inform Assoc 14:41-47, 2007
22. Randell R, Mitchell N, Dowding D, et al: Effects of computerised decision support systems on nursing performance and patient outcomes: A systematic review. J Health Serv Res Policy 12:242-251, 2007
23. Kawamoto K, Houtian CA, Balas EA, et al: Information in practice systematic review of trials to identify features critical to success. BMJ 330:765, 2005
24. Fox J, Jackson-Smale A: Why should you trust a decision support system? Toward a quality and safety culture for knowledge based systems, in Barahonan P, leaders. Knowledge and Decisions in Health Telematics: The Next Decade. Amsterdam, IOS Press, 1994, pp 81-89
25. Miller RA: Computer-assisted diagnostic decision support. History, challenges, and possible paths forward. Adv Heal Sci Educ 14:89–106, 2009
26. European Council: Council directive 93/42/EEC of 14 June 1993 concerning medical devices. Off J Eur Communities 169, 1993
27. The European Parliament and The Council of the European Union: Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EU) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/ EEC and 93/42/EEC. Off J Eur Union, 2017. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745
71. Sujan MA, Huang H, Braithwaite J: Learning from incidence in health care: Critique from a safety-II perspective. Saf Sci 99:115–121, 2016
72. Nieuwenhuijse MJ, Nelissen RGHH, Schoones JW, et al: Appraisal of evidence base for introduction of new implants in hip and knee replacement: A systematic review of five widely used device technologies. BMJ 349:1-12, 2014
73. Kesselheim AS, Rajan PV: Regulating incremental innovation in medical devices. BMJ 349:9-10, 2014
74. Sedrakyan A, Campbell B, Merino JG, et al: IDEAL-D: A rational framework for evaluating and achieve this goal. BMJ 353:1-7, 2016
75. Hirst A, Philippou Y, Blazeby J, et al: No surgical innovation without evaluation: Evolution and further development of the IDEAL framework and recommendations. Ann Surg 269:211-220, 2019
76. US Food and Drug Administration: Digital Health Innovation Action Plan, 2017, https://www.fda.gov/media/106331/download
77. Oelze I, Neeser K, Müller E: PP31 medical device Regulations: What is new? Int J Technol Assess Health Care 35:42-43, 2019
78. Hopkin P: Loss control, in Fundamentals of Risk Management: Understanding, Evaluating and Implementing Effective Risk Management (ed 4). London, UK, Kogan Page Limited, 2017, pp 152-157
79. Youngberg BJ, Ealy TV: Setting up a risk management department, in Youngberg BJ (ed): Principles of Risk Management and Patient Safety. Sudbury, MA, Jones & Bartlett, 2010, pp 43-62
80. Vincent C, Amalberti R: Approaches to safety: One size does not fit all, in Safer Healthcare: Strategies for the Real World. Springer, 2016, pp 27-38
81. Hilborn RC: Sea gulls, butterflies, and grasshoppers: A brief history of the butterfly effect in nonlinear dynamics. Am J Phys 72:425-427, 2004
82. Ravitz AD, Sapirstein A, Pham JC, et al: Systems approach and systems engineering applied to health care: Improving patient safety and health care delivery. Johns Hopkins APL Tech Dig (Applied Phys Lab) 31:354-365, 2013
83. Underwood P, Waterson P: Systemic accident analysis: Examining the gap between research and practice. Accid Anal Prev 55:154-164, 2013
84. Leveson NG: A new accident model for engineering safer systems. Saf Sci 42:237-270, 2004
85. Moshi M, Paras J, Tooher R, et al: OP143 assessment of mHealth apps: Is current regulation policy adequate? Int J Technol Assess Health Care 35, 2019
86. Lamph S: Regulation of medical devices outside the European Union. J R Soc Med 105:s12-21, 2012